Replies to post #306160 on Avid Bioservices Inc (CDMO)

[JJ1223]

Agree that he opened his mouth without a clear understanding of what is going on with Bavi, and he severely underestimates many shareholder's interest in the internal commercial development of PS Targeting with Bavituximab. Apparently he totally discounts the work and beliefs of Wolchok, Birge, NCCN, MSK and others. If he is going to make progress toward his takeover goal, he needs to do more homework on PS. He will have to make a compelling case on why all clinical development must stop short of goal, or admit he made a mistake. If he thinks Avid should be expanded beyond its current award winning position and record growth, why let Ronin take over. Doubt they could do better than King and Gagnon. We should replace two BOD members and move forward with our current path of clinical development on Bavi and Exosomes and let Avid grow. IMHO

[biopharm]

"Maybe the letter should have stated to cease all pre clinical activity and place all future clinical activity on hold until the company is on firm financial footing. "

BINGO you win

No vote for Ronin I say when Ronin says "Peregrine must immediately cease all clinical development activities" and Dr Jedd Wolchok already backing PS Targeting ....spoke out for PS Targeting and would be at risk of being shut out due to Ronins way of thinking...

Any current clinical development activity ( like MSK and NCCN....etc ) must move forward and Ronin must be a no vote unless Ronin makes big changes

Sounds like Ronin backers don't want Dr Jedd Wolchok aligning certain parties with PS Targeting and is this why Ronin said Peregrine better not do a deal without a vote?

If Peregrine makes a good deal that gets the pps up in $45+ then it would likely not be thwarted by Ronin ....time will tell

[exwannabe]

I agree with your point that PPHM does not presently have any clinical activity. The NCCN trials are not theirs to stop (and I suspect they have already committed the Bavi).

One possibility is that we are talking headcounts. Could there be employees at PPHM who's positions can not be justified based on the present state? Hard to know, as we have limited visibility.

They have Shan (clinical and regulatory) and Garnick. Plus who knows how many slaves under them. Might the overhead here be the target?

I do not claim to know, only tossing out possibilities.

BTW, one clear point I would disagree with Ronin on is not going ahead with the POC on the Exosome test (assuming the validation tests look good). This will not cost much at all.